Browse IP Listings

A comprehensive portfolio of 12 granted US patents covering novel base editing methods using CRISPR-Cas9 derivatives. The portfolio includes methods for precise adenine-to-inosine editing in mammalian cells, with applications in genetic disease correction. Clinical efficacy demonstrated in sickle cell disease models with >95% on-target editing efficiency.

Granted patent covering a proprietary ionizable lipid nanoparticle (LNP) formulation optimized for mRNA delivery to hepatocytes. The technology demonstrates 10x improved endosomal escape compared to first-generation LNPs, with validated in vivo efficacy in NHP studies. Broad applications in gene therapy and mRNA vaccine delivery.

A curated multi-omics dataset spanning genomics, transcriptomics, proteomics, and clinical outcomes for 50,000 de-identified cancer patients across 12 tumor types. Data collected over 8 years from 6 academic medical centers. Includes matched tumor/normal samples, treatment histories, and 5-year survival data. IRB approved, HIPAA compliant.

Longitudinal microbiome profiling dataset tracking 2,400 subjects over 3 years, correlating gut microbiome composition changes with inflammatory biomarker levels (CRP, IL-6, TNF-α). Includes 16S rRNA and shotgun metagenomic sequencing, dietary records, and clinical metadata. Strong basis for microbiome-based therapeutic development.

Non-exclusive license to a proprietary deep learning platform for protein tertiary structure prediction, achieving sub-1Å RMSD accuracy on benchmark datasets. The platform has been validated on 400+ novel protein families not represented in PDB. Includes trained model weights, inference pipeline, and 12 months of technical support.

Exclusive license for commercializing a microfluidics-based single-cell RNA sequencing platform capable of processing 100,000 cells per run at 50% lower cost than existing platforms. Validated in clinical research settings with CE marking in progress. Includes manufacturing know-how and supplier agreements.

A first-in-class covalent small molecule inhibitor selectively targeting KRAS G12C mutation in non-small cell lung cancer. IC50 of 0.8 nM in biochemical assay, EC50 of 12 nM in NCI-H358 cell line. Excellent oral bioavailability (78% in rat PK studies) and CNS penetration. IND-enabling studies completed, ready for Phase I.

A highly selective JAK1 inhibitor (>100x selectivity over JAK2/JAK3/TYK2) developed for topical treatment of moderate-to-severe atopic dermatitis. Demonstrates dose-dependent reduction of TSLP and IgE in murine AD model. Clean off-target selectivity panel (>1000 kinases). Pharmaceutical-grade synthesis route established with 3 CMO relationships.